Donald C. Anderson
Plus aucun poste en cours
Profil
Donald C.
Anderson worked as a Principal at Pharmacia & Upjohn, Inc. and Aventis Pharmaceuticals, Inc. He also held the position of Vice President-Discovery Research at Middlebrook Pharmaceuticals, Inc. and Chief Medical Officer at Sierra Oncology, Inc. Prior to his industry experience, he was a Professor at Baylor College of Medicine.
Anderson also served as a Scientific Advisor at AureoGen, Inc. He holds a doctorate from the University of Washington and an undergraduate degree from The University of Colorado.
Anciens postes connus de Donald C. Anderson
| Sociétés | Poste | Fin |
|---|---|---|
AureoGen, Inc.
 AureoGen, Inc. BiotechnologyHealth Technology AureoGen, Inc. develops a novel genetic-engineering technology for the discovery and production of cyclic peptide based drugs. It focuses on chemical modification of cyclic peptide lead compounds, non-ribosomal peptide synthetases engineering, and chemo-enzymatic synthesis. The company was founded by Ake P. Elhammer and Jerry L. Slightom on August 12, 2003 and is headquartered in Kalamazoo, MI. | Corporate Officer/Principal | - |
| Baylor College of Medicine | Corporate Officer/Principal | - |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | - |
| Pharmacia & Upjohn, Inc. | Corporate Officer/Principal | - |
| SIERRA ONCOLOGY, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Donald C. Anderson
| University of Washington | Doctorate Degree |
| The University of Colorado | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 5 |
|---|---|
| Pharmacia & Upjohn, Inc. | Health Technology |
Middlebrook Pharmaceuticals, Inc.
 Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
AureoGen, Inc.
AureoGen, Inc. BiotechnologyHealth Technology AureoGen, Inc. develops a novel genetic-engineering technology for the discovery and production of cyclic peptide based drugs. It focuses on chemical modification of cyclic peptide lead compounds, non-ribosomal peptide synthetases engineering, and chemo-enzymatic synthesis. The company was founded by Ake P. Elhammer and Jerry L. Slightom on August 12, 2003 and is headquartered in Kalamazoo, MI. | Health Technology |
